arrow
J

Jens Lundgren

Copenhagen University Hospital Rigshospitalet
H指数:111
被引数:6.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prophylaxis Durations and Risks of Cytomegalovirus Infection and Disease in Solid Organ Transplant Recipients: An International, Multicenter Cohort Study

巨细胞病毒感染和疾病在实体器官移植受者中的预防持续时间及风险:一项国际、多中心队列研究

2026-10-120
OAAI
Cardiovascular Disease Risk with Integrase Inhibitor-based Antiretroviral Therapy: A Causal Inference Analysis in RESPOND

整合酶抑制剂为基础的抗逆转录病毒疗法的心血管疾病风险:一项在RESPOND中的因果推断分析

2026-08-060
OAAI
Early high-resolution immune profiles are associated with survival, relapse and graft-versus-host-disease after allogeneic hematopoietic cell transplantation

早期高分辨率免疫谱与异基因造血细胞移植后的生存、复发和移植物抗宿主病相关

2026-05-300
OAAI
Ensitrelvir for the treatment of hospitalized adults with COVID-19: an international phase 3 randomized placebo-controlled trial

恩塞特雷韦治疗住院成人COVID-19:一项国际多中心III期随机安慰剂对照试验

2026-04-220
PRE
Immunogenicity of SARS-CoV-2 primary vaccination and boosters in patients with immune-mediated inflammatory diseases: Impact of immunosuppressive therapy

SARS-CoV-2基础免疫和加强针在免疫介导性炎症疾病患者中的免疫原性:免疫抑制治疗的影响

Vaccine
IF3.5
2025-12-230
OAAI
Mortality using raltegravir versus other integrase strand-transfer inhibitors in people with HIV in Europe and Australia: a prospective multicentre study

使用拉替拉韦与其他整合酶链转移抑制剂在欧澳地区HIV感染者中的死亡率比较:一项前瞻性多中心研究

2025-09-200
PREAI
The Diagnostic Value of Soluble Epstein-Barr Virus BZLF1 Protein in Posttransplant Lymphoproliferative Disease Among Solid Organ and Hematopoietic Cell Transplant Recipients

可溶性EB病毒BZLF1蛋白在实体器官和造血细胞移植受者中移植后淋巴增殖性疾病的诊断价值

2025-09-010
PRE
Immunogenicity and Safety of the Coronavirus Disease 2019 Messenger RNA Vaccine Coadministered With Influenza and 23-valent Pneumococcal Polysaccharide Vaccines

新冠病毒疾病2019信使核糖核酸疫苗与流感疫苗和23价肺炎球菌多糖疫苗联合接种的免疫原性和安全性

2025-09-010
PRE
Associations Between Pre-Transplantation T Cell Populations and Acute Cellular Rejection Post-Liver Transplantation—Results From a Prospective Cohort Study

移植前T细胞群体与肝移植术后急性细胞排斥反应之间的关联——前瞻性队列研究的结果

2025-08-190
OAAI
Evaluation of antiretroviral regimen switching options in adults with HIV with sustained viral load non-suppression on dolutegravir, lamivudine, and tenofovir in eastern, central, southern, and western Africa: a modelling study

评估在东、中、南、西非洲成人HIV患者中,对持续病毒载量未抑制于多替拉韦、拉米夫定和替诺福韦方案的抗逆转录病毒治疗方案切换选择的建模研究

2025-06-240
OAAI
Evaluation of the Feasibility and Efficacy of Point-of-Care Antibody Tests for Biomarker-Guided Management of Coronavirus Disease 2019
2024-09-120
PRE